NCT06112704

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

Recruiting now Phase 2 Last updated 2 December 2024

What this trial tests

Phase 2 trial testing HS-20093 in Advanced Solid Tumor in 220 participants. Currently enrolling.

Timeline

6 February 2024

Primary endpoint
31 July 2026

31 December 2026

Quick facts

Lead sponsor	Hansoh BioMedical R&D Company
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	220
Start date	6 February 2024
Primary completion	31 July 2026
Estimated completion	31 December 2026
Sites	21 locations across China

Drugs / interventions tested

• HS-20093 — full drug profile →

Conditions studied

• Advanced Solid Tumor — all drugs for Advanced Solid Tumor →

Sponsor

Hansoh BioMedical R&D Company — full company profile →

Who can join

18 and older, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Evolving standards and future directions for systemic therapies in cervical cancer.
   Ang DJM, Chan JJ. · · 2024 · cited 14× · PMID 38282261 · DOI 10.3802/jgo.2024.35.e65
2. Non-immune functions of B7-H3: bridging tumor cells and the tumor vasculature.
   Wu S, Hu C, Hui K, Jiang X. · · 2024 · cited 12× · PMID 38952550 · DOI 10.3389/fonc.2024.1408051
3. Advancements in antibody-drug conjugates as cancer therapeutics.
   Fong JY, Phuna Z, Chong DY, Heryanto CM, et al · · 2025 · cited 11× · PMID 40814440 · DOI 10.1016/j.jncc.2025.01.007
4. B7-H3 in Cancer Immunotherapy-Prospects and Challenges: A Review of the Literature.
   Mielcarska S, Kot A, Dawidowicz M, Kula A, et al · · 2025 · cited 5× · PMID 40801642 · DOI 10.3390/cells14151209
5. Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions.
   Chen B, Zheng X, Wu J, Chen G, et al · · 2025 · cited 4× · PMID 41184856 · DOI 10.1186/s12943-025-02489-2
6. Current Trends in Clinical Trials of Prodrugs.
   Boreski D, Schmid VF, Bosquesi PL, Dos Santos JL, et al · · 2025 · cited 2× · PMID 40006024 · DOI 10.3390/ph18020210
7. Expanding the potential of antibody-drug conjugates in gastrointestinal malignancies: beyond HER2 targets.
   Ntellas P, Athauda A, Sugiyama K, Le ML, et al · · 2025 · PMID 41646266 · DOI 10.1016/j.esmogo.2025.100154
8. Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment.
   Marchesi S, Marinello A, Ambrosini P, Cavalli C, et al · · 2025 · PMID 40603576 · DOI 10.1038/s41698-025-01011-7